GW Pharmaceuticals PLC - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for GW Pharmaceuticals PLC Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

GW Pharmaceuticals PLC. The Group's principal activity is developing a range of new medicines based on cannabis and other controlled drugs. The Group's lead programme is the development of a portfolio of cannabinoid medicines, including Sativex, to meet patient needs in a wide range of therapeutic indications. The principal initial target areas are Multiple Sclerois (MS) spasticity, neuropathic pain, neuropathic pain in MS and cancer pain. The Group's research also includes the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. The Group operates predominantly in the United Kingdom.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report